Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Technetium Tc 99m-Labeled Red Blood Cells
Overview
What is Ultratag?
Ultratag™ RBC (kit for the preparation of technetium Tc 99m-labeled red blood cells) is a sterile, nonpyrogenic, diagnostic kit for the in vitro preparation of technetium Tc 99m-labeled red blood cells.
Each kit consists of three separate nonradioactive components:
1. A 10 milliliter reaction vial containing:
Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mg
Prior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.
2. Syringe I contains:
Sodium Hypochlorite – 0.6 mg in Sterile Water for Injection
The total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.
3. Syringe II contains:
Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for Injection
The total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.
What does Ultratag look like?
What are the available doses of Ultratag?
Sorry No records found.
What should I talk to my health care provider before I take Ultratag?
Sorry No records found
How should I use Ultratag?
Technetium Tc 99m-labeled red blood cells are used for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding.
The Instructions for Preparation must be carefully followed for preparing technetium Tc 99m-labeled red blood cells using Ultratag™ RBC.
The suggested dose range of technetium Tc 99m-labeled red blood cells in the average patient (70 kg) is 370 MBq (10 mCi) to 740 MBq (20 mCi).
The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Aseptic procedures and a shielded syringe should be employed in preparing and withdrawing doses for administration to patients. The user should wear waterproof gloves during the administration procedure.
What interacts with Ultratag?
None known.
What are the warnings of Ultratag?
In a few patients on bromocriptine mesylate, particularly on long-term and high-dose treatment, retroperitoneal fibrosis has been reported. To ensure recognition of retroperitoneal fibrosis at an early reversible stage it is recommended that its manifestations (e.g., back pain, edema of the lower limbs, impaired kidney function) should be watched in this category of patients. Bromocriptine mesylate medication should be withdrawn if fibrotic changes in the retroperitoneum are diagnosed or suspected.
What are the precautions of Ultratag?
General
The components of the kit are sterile and nonpyrogenic. It is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation.
The contents of the kit are intended only for use in the preparation of technetium Tc 99m-labeled red blood cells and are NOT to be administered directly to the patient.
The contents of this kit are not radioactive. After sodium pertechnetate Tc 99m is added, however, adequate shielding of the final preparation must be maintained.
Technetium Tc 99m-labeled red blood cells must be handled with care to ensure minimum radiation exposure to the patient, consistent with proper patient management, and to ensure minimum radiation exposure to occupational workers.
The labeled red blood cells must be reinjected only into the patient from whom the blood was drawn.
Nuclear medicine procedures involving withdrawal and reinjection of blood have the potential for transmission of blood borne pathogens. Procedures should be implemented to avoid administration errors and viral contamination of personnel during blood product labeling. A system of checks similar to the ones used for administering blood transfusions should be routine.
Clinical trials were conducted with a variety of prescription and nonprescription medications and showed no significant effect on the in vitro labeling efficiency of Ultratag™ RBC. Unlike stannous pyrophosphate red blood cell kits, heparinized patients (11) showed minimal interference with Ultratag™ RBC labeling efficiency (95% with heparin, 97% without heparin).
It is recommended that the labeled red blood cells be administered within 30 minutes of preparation or as soon as possible thereafter. A small study showed that technetium Tc 99m-labeled red blood cells prepared with Ultratag™ RBC have equivalent in vivo labeling efficiency when administered both immediately after preparation (5 patients studied) and at 6 hours after preparation (6 patients studied) with a 24-hour labeling efficiency averaging 97% for both groups.
Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No long term animal studies have been performed to evaluate carcinogenic or mutagenic potential or to determine the effects on male or female fertility.
Pregnancy Category C
Animal reproduction studies have not been conducted with technetium Tc 99m-labeled red blood cells. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Technetium 99m-labeled red blood cells should be administered to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.
Nursing Mothers
Technetium Tc 99m is excreted in human milk during lactation. Therefore, formula feedings should be substituted for breast feeding.
Pediatric Use
Safety and efficacy in pediatric patients have not been established.
Array
What are the side effects of Ultratag?
None known.
What should I look out for while using Ultratag?
None known.
None known.
What might happen if I take too much Ultratag?
Sorry No Records found
How should I store and handle Ultratag?
As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from oxaliplatin. The use of gloves is recommended. If a solution of oxaliplatin contacts the skin, wash the skin immediately and thoroughly with soap and water. If oxaliplatin contacts the mucous membranes, flush thoroughly with water.Procedures for the handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published . There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from oxaliplatin. The use of gloves is recommended. If a solution of oxaliplatin contacts the skin, wash the skin immediately and thoroughly with soap and water. If oxaliplatin contacts the mucous membranes, flush thoroughly with water.Procedures for the handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published . There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.Catalog Number 068.Ultratag™ RBC consists of three separate nonradioactive components:1. A 10 milliliter reaction vial containing:Stannous Chloride, Dihydrate (SnCl•2HO) – 50 ug minimum Stannous Chloride, Dihydrate (SnCl•2HO) – 96 ug theoretical Tin Chloride (Stannous and Stannic), Dihydrate (as SnCl•2HO) – 105 ug maximumSodium Citrate, Dihydrate – 3.67 mgDextrose, Anhydrous – 5.50 mgPrior to lyophilization, the pH is adjusted to 7.1 to 7.2 with sodium hydroxide. The contents of the vial are lyophilized and stored under argon.2. Syringe I contains:Sodium Hypochlorite – 0.6 mg in Sterile Water for InjectionThe total volume of this syringe is 0.6 mL. Sodium hydroxide may have been added for pH adjustment. The pH of this solution is 11 to 13. The syringe must be protected from light to prevent degradation of the light-sensitive sodium hypochlorite.3. Syringe II contains:Citric Acid, Monohydrate – 8.7 mg Sodium Citrate, Dihydrate – 32.5 mgDextrose, Anhydrous – 12.0 mg in Sterile Water for InjectionThe total volume of this syringe is 1.0 mL. The pH range of this solution is adjusted to 4.5 to 5.5 with sodium citrate or citric acid.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
In vitro Tc 99m red blood cell labeling is accomplished by adding 1.0 to 3.0 milliliters of autologous whole blood, anticoagulated with heparin or Anticoagulant Citrate Dextrose Solution (ACD), to the reaction vial. A portion of the stannous ion in the reaction vial diffuses across the red blood cell membrane and accumulates intracellularly. The in vitro Tc 99m red blood cell labeling efficiency can decrease in the presence of excess ACD. Excess ACD apparently impairs the diffusion of stannous ion across the red blood cell membrane. Therefore, the ACD concentration used for blood collection should not exceed 0.15 mL ACD per mL of blood. Sodium hypochlorite is then added to the reaction vial to oxidize the extracellular stannous ion. Since the hypochlorite does not cross the red blood cell membrane, the oxidation of stannous ion is selective for the extracellular tin. A citric acid, sodium citrate and dextrose solution is then added to the reaction vial to sequester any residual extracellular stannous ion, rendering it more readily available for oxidation by sodium hypochlorite.
Radioactive labeling of the red blood cells is completed by addition of sodium pertechnetate Tc 99m to the oxidized reaction vial. The pertechnetate Tc 99m diffuses across the red blood cell membrane and is reduced by the intracellular stannous ion. The reduced technetium Tc 99m cannot diffuse out of the red blood cell. The red blood cell labeling is essentially complete within 20 minutes of sodium pertechnetate Tc 99m addition to the reaction vial. Red blood cell labeling efficiency of ≥95% is typically obtained using this in vitro labeling procedure. In vitro Tc 99m red blood cell labeling efficiency can decrease when excessive amounts of Tc 99 are allowed to accumulate in the sodium pertechnetate Tc 99m generator eluate; in this situation, efficiency decreases even further if excess (i.e. >0.15 mL per mL of blood) ACD buffer is used. Therefore, long Tc 99 in-growth times are to be avoided; the use of fresh (≤24 hour in-growth time) sodium pertechnetate Tc 99m generator eluate is recommended. After the labeling procedure is completed, the technetium Tc 99m-labeled red blood cells are then reinjected intravenously into the patient for gamma scintigraphic imaging.
Following intravenous injection, the technetium Tc 99m-labeled red blood cells distribute within the blood pool with an estimated volume of distribution of approximately 5.6% of bodyweight. The technetium Tc 99m is well retained in the blood pool with an estimated biological half-life of approximately 29 hours. Of the total technetium Tc 99m retained in the whole blood pool 24 hours after administration, 95% remains bound to the red blood cells. Approximately 25% of the injected dose is excreted in the urine in the first 24 hours.
Non-Clinical Toxicology
None known.None known.
The components of the kit are sterile and nonpyrogenic. It is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation. The contents of the kit are intended only for use in the preparation of technetium Tc 99m-labeled red blood cells and are NOT to be administered directly to the patient. The contents of this kit are not radioactive. After sodium pertechnetate Tc 99m is added, however, adequate shielding of the final preparation must be maintained. Technetium Tc 99m-labeled red blood cells must be handled with care to ensure minimum radiation exposure to the patient, consistent with proper patient management, and to ensure minimum radiation exposure to occupational workers. The labeled red blood cells must be reinjected only into the patient from whom the blood was drawn. Nuclear medicine procedures involving withdrawal and reinjection of blood have the potential for transmission of blood borne pathogens. Procedures should be implemented to avoid administration errors and viral contamination of personnel during blood product labeling. A system of checks similar to the ones used for administering blood transfusions should be routine. Clinical trials were conducted with a variety of prescription and nonprescription medications and showed no significant effect on the in vitro labeling efficiency of Ultratag™ RBC. Unlike stannous pyrophosphate red blood cell kits, heparinized patients (11) showed minimal interference with Ultratag™ RBC labeling efficiency (95% with heparin, 97% without heparin). It is recommended that the labeled red blood cells be administered within 30 minutes of preparation or as soon as possible thereafter. A small study showed that technetium Tc 99m-labeled red blood cells prepared with Ultratag™ RBC have equivalent in vivo labeling efficiency when administered both immediately after preparation (5 patients studied) and at 6 hours after preparation (6 patients studied) with a 24-hour labeling efficiency averaging 97% for both groups. Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.
None known.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
517Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).